HP
CRL icon

HealthInvest Partners’s Charles River Laboratories CRL Stock Holding History

HealthInvest Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$2.92M Sell
26,712
-34,100
-56% -$3.71M 6.17% 2
2017
Q3 		$6.57M Sell
60,812
-9,400
-13% -$966K 7.67% 5
2017
Q2 		$7.1M Sell
70,212
-15,400
-18% -$1.42M 8.86% 4
2017
Q1 		$7.7M Sell
85,612
-25,500
-23% -$2.17M 11.81% 5
2016
Q4 		$8.47M Sell
111,112
-7,500
-6% -$570K 7.8% 4
2016
Q3 		$9.88M Sell
118,612
-31,000
-21% -$2.6M 7.36% 5
2016
Q2 		$12.3M Sell
149,612
-28,695
-16% -$2.36M 5.66% 11
2016
Q1 		$13.5M Sell
178,307
-4,400
-2% -$326K 6.34% 7
2015
Q4 		$14.7M Sell
182,707
-157,613
-46% -$11.4M 6.91% 8
2015
Q3 		$21.6M Buy
340,320
+100,000
+42% +$7.18M 12.78% 4
2015
Q2 		$16.9M Buy
240,320
+96,000
+67% +$7.1M 8.64% 7
2015
Q1 		$11.4M Sell
144,320
-17,000
-11% -$1.25M 7.93% 9
2014
Q4 		$10.3M Hold
161,320
– – 8.49% 4
2014
Q3 		$9.64M Sell
161,320
-116,693
-42% -$6.68M 7.03% 6
2014
Q2 		$14.9M Buy
278,013
+63,000
+29% +$3.46M 8.38% 4
2014
Q1 		$13M Sell
215,013
-3,887
-2% -$227K 9.25% 1
2013
Q4 		$11.6M Buy
+218,900
New +$11M 11.55% 2

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HealthInvest Partners's CRL Position: Q4 2017 in Review

HealthInvest Partners reduced its Charles River Laboratories (CRL) stake by 56% in Q4 2017, selling an estimated $3.71M and leaving 26,712 shares worth $2.92M. The position accounts for 6.17% of the portfolio, ranked #2.

HealthInvest Partners first reported a position in CRL in Q4 2013 and has held it in 17 quarters since. The position peaked at $21.6M in Q3 2015. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • HealthInvest Partners held 26,712 shares of Charles River Laboratories worth $2.92M as of Q4 2017.
  • HealthInvest Partners sold 34,100 Charles River Laboratories shares in Q4 2017, an estimated $3.71M.
  • Charles River Laboratories made up 6.17% of HealthInvest Partners's portfolio in Q4 2017, its #2 holding.
  • HealthInvest Partners first reported a position in Charles River Laboratories in Q4 2013 and has held it in 17 quarters since.
  • HealthInvest Partners's Charles River Laboratories position peaked at $21.6M in Q3 2015.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on HealthInvest Partners's 13F filing for Q4 2017, filed 9 Feb 2018.